New injection aims to tame rheumatoid arthritis
NCT ID NCT07230353
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new biologic drug called plamotamab in 68 adults with moderate to severe rheumatoid arthritis (RA) who haven't gotten enough relief from other treatments. The drug is given as a shot under the skin, and the main goal is to see if it's safe and tolerable. Researchers will also measure how the drug moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
plamotamab (a biologic drug given as an injection under the skin)
What this could lead to
If it works, this could point toward a new treatment option for people with rheumatoid arthritis who haven't responded well to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 68 participants, so it's primarily checking safety, not effectiveness. The drug may cause side effects or not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Xencor Investigative Site
RECRUITINGTbilisi, Georgia
-
Xencor Investigative Site
RECRUITINGChisinau, Moldova
-
Xencor Investigative Site
RECRUITINGAuckland, New Zealand